Belgium· BE-AMP-SAM660926-00
Livmarli 9.5 mg/ml
A maralixibat chloride product containing maralixibat chloride, registered in Belgium by Mirum Pharmaceuticals International. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Maralixibat chloride is registered in 11 of 19 countries.
Countries holding a registration under ATC A05AX04 (maralixibat chloride), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Maralixibat chloride · ATC A05AX04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Maralixibat Chloride
- Manufacturer
- Mirum Pharmaceuticals International
- Country
- Belgium (BE)
- ATC code
- A05AX04
- ATC class
- Maralixibat chloride
- Defined daily dose
- 28.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4741914
- be_apb7741812
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Maralixibat chloride in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandLivmarli 9.5 mg/ml, Lösung zum EinnehmenMirum Pharmaceuticals AG
- CzechiaLIVMARLIMirum Pharmaceuticals International B.V., Amsterdam
- SpainLIVMARLI 9,5 MG/ML SOLUCION ORALMirum Pharmaceuticals International B.V.
- FinlandLivmarliMirum Pharmaceuticals International B.V.
- IrelandLivmarli 9.5 mg/mL oral solutionMirum Pharmaceuticals International B.V.
- IcelandLivmarliMirum Pharmaceuticals International B.V.
- PolandLivmarliMirum Pharmaceuticals International B.V.
- SwedenLIVMARLI 9,5 mg/ml Oral lösningMirum Pharmaceuticals International B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Livmarli
- Liechtenstein · Livmarli
- Norway · Livmarli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5145cbfc-108f-403b-b8bf-1ecdc8d7b023 GET /v1/drugs/5145cbfc-108f-403b-b8bf-1ecdc8d7b023?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oral solution",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Livmarli 9.5 mg/ml",
"name_fr": "Livmarli 9.5 mg/ml",
"name_nl": "Livmarli 9.5 mg/ml",
"amp_code": "SAM660926-00",
"strengths": [
"9.5000",
"9.5000",
"364.5000"
],
"pack_count": 1,
"substances": [
"Maralixibat Chloride",
"Maralixibat",
"Disodium Edetate",
"Propylene Glycol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Maralixibat Chloride",
"authorisation_numbers": [
"EU/1/22/1704/001"
]
}See everything about maralixibat chloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.